NSNikunj Solanki

Nikunj Solanki

*This is an algorithmically generated author record based on publicly available information.

Nikunj Solanki has a total of 21 co-authors. Here are the top co-authors by number of shared publications:

  • Ajay Shirsat

    Hon. Shri Babanrao Pachpute Vichardhara Trust’s Group of Institutions, Faculty of Pharmacy

    1 shared publication
  • Anup Lal Yadav

    School of Engineering and Technology, CGC University

    1 shared publication
  • Arnabjyoti Deva

    Faculty of Paramedical Sciences, Assam down town University, Sankar Madhab Path, Gandhi Nagar, Panikhaiti

    1 shared publication
  • Ashok Dalimbe

    Hon. Shri Babanrao Pachpute Vichardhara Trust’s Group of Institutions, Faculty of Pharmacy

    1 shared publication
  • Diksha Jindal

    Adesh Institute of Pharmacy and Biomedical Sciences, Adesh University

    1 shared publication
  • G Usha Kiranmai

    University College of Pharmaceutical Sciences, Kakatiya University

    1 shared publication

Latest Publications

  • Open Access

    Decision-Centric Explainable AI for QbD Optimization of Ultrasound-Triggered Drug- Loaded Microbubbles and Control Strategy Development

    by Anup Lal Yadav, Sonal Solanki, Nikunj Solanki, Vishin Patil, Sreenath Sriram, Yamsani Kumar, Sreekanth Thota, Mahesh Kumar Posa, Suvarna Nirmal, Meghana Raykar, et al.

    A decision-centric workflow was developed to link a QbD-defined design space with interpretable surrogate modeling for rapid selection of ultrasound-triggered doxorubicin-loaded chitosan microbubbles. A 15-run Box–Behnken design spanning chitosan, palmitic acid, and Pluronic F68 was used to quantify three critical quality attributes (CQAs)—mean size, encapsulation efficiency (EE), and burst release at 40 s (Burst40)—and to train response-specific surrogates evaluated by leave-one-out cross-validation (LOOCV). The DoE produced a broad performance envelope (size 2.35–4.85 µm; EE 60–82%; Burst40 55.6–95%) with clear composition-driven trade-offs, notably between EE and acoustic responsiveness. A regularized polynomial surrogate (PolyRidge) provided strong LOOCV performance for size (R²=0.885; RMSE = 0.264 µm) and EE (R²=0.871; RMSE = 2.18%), whereas Burst40 was only moderately predictable (R²=0.501; RMSE = 8.61%), consistent with threshold-like cavitation and microstructure sensitivity. Digital screening with multi-objective desirability and explainability (SHAP, permutation importance, partial dependence, LIME) shortlisted manufacturable candidates; experimental validation showed QbD/RSM was better calibrated for absolute size and EE, while both modeling approaches remained similarly limited for Burst40. Importantly, shortlisted formulations preserved suppressed baseline release and pronounced ultrasound-enhanced release, yielding trigger-dependent cytotoxicity and increased apoptotic commitment in MCF-7 cells.


  • Open Access

    From QbD to Explainable AI: Interpretable Random Forest Surrogates for Design Space Understanding of Voriconazole–β-Cyclodextrin Inclusion Complexes

    by Sonal Solanki, Garima Kumari, Nikunj Solanki, Diksha Jindal, G Usha Kiranmai, Snehal Chakorkar, Arnabjyoti Deva, Narender Boggula, Sreekanth Thota, Manisha Zaware, et al.

    Background Voriconazole formulation development is often constrained by limited aqueous solubility and variable dissolution behavior. β-Cyclodextrin (β-CD) inclusion complexation prepared by solvent-free co-grinding is a practical solubility-enhancement strategy. A recent Quality-by-Design (QbD) study optimised this system using a central composite design (CCD); however, polynomial response surfaces can be difficult to interpret locally across the design space. Objective To perform an explainable artificial intelligence (XAI) secondary reanalysis of a published QbD CCD dataset for voriconazole–β-CD inclusion complexes, generating interpretable Random Forest (RF) surrogates for design-space understanding and comparing model behavior against published QbD checkpoints. Methods Factor–response data (13 CCD runs) were extracted exactly as reported for β-CD amount (A, mg) and grinding time (B, min) with responses solubility (Y1, mg/mL) and cumulative drug release (Y2, %CDR). Two RF regression surrogates (RF–Y1 and RF–Y2) were trained and evaluated by leave-one-out cross-validation (LOOCV). Published checkpoints were used for benchmarking against QbD predictions. Explainability was implemented using TreeSHAP, permutation feature importance (PFI), partial dependence/ICE plots, and LIME. RF-based response surfaces and a multi-response desirability map were generated to identify high-performance regions. Results LOOCV indicated modest predictive performance (Y1: R²=0.1629, MAE = 11.2217, RMSE = 14.4720; Y2: R²=0.2208, MAE = 12.3883, RMSE = 15.5143). RF design-space mapping indicated increasing Y1 and Y2 with higher A and B, with a broad high-response region. The RF desirability optimum occurred at A = 544.99 mg and B = 26.84 min with predicted Y1 = 66.09 mg/mL, Y2 = 89.08%, and desirability = 0.887. At the published high-performance checkpoint (A = 600 mg, B = 30 min), RF predictions closely matched the experimental results (Y1 ≈ 66.09 vs 65.86 mg/mL; Y2 ≈ 89.08 vs 85.93%), whereas the QbD polynomial overpredicted, especially for Y2. SHAP global importance suggested A dominated Y1 (mean |SHAP|: A = 7.37; B = 3.78), while Y2 depended on both factors (A = 7.48; B = 7.82); PFI supported strong influence of A (ΔMAE: Y1 A ≈ 11.03, B ≈ 5.42; Y2 A ≈ 12.31, B ≈ 5.97). Conclusion Explainable ML did not replace QbD; it augmented a published QbD dataset with transparent, multi-view interpretability and an alternative design-space depiction. RF + XAI triangulated factor priority (carrier-driven solubility; joint carrier–process control of release), highlighted plateau-like high-performance regions, and provided calibration-friendly predictions at the optimised condition. This workflow offers a practical template for integrating explainable AI into formulation-oriented QbD analyses.